English
Chinese (Simplified)
About Us
INmuneBio
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.
Products
INKmune™
INKmune is a biologic delivery system that allows us to deliver the missing S1 (priming signal) to the patient’s resting NK cells. INKmune is delivered by a simple IV infusion.
Products
INB03
INB03 is a checkpoint inhibitor that targets myeloid-derived suppressor cells (MDSC) in the tumor microenvironment that produce an immunosuppressive shield that prevents the patient’s immune system from attacking the cancer.
Products
XPro1595
XPro1595 targets neuroinflammation which may slow or stop the progression of the cognitive and psychiatric symptoms of Alzheimer’s patients and improve in the overall quality of life of the patient and their care-givers.
Stay Tuned
Latest News
- May 16, 2019 INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital
- May 15, 2019 INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update
- May 07, 2019 INmune Bio Closes Private Placement of Approximately $4.1 Million of Common Stock, Led by Insiders and Existing Shareholders
| Have a Question? 858 964 3720 |
| Email Us dmoss@inmunebio.com |
| Opening Hours M - F 8am to 5pm PST |